Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:AGIO
- CUSIP: N/A
- Web: www.agios.com
Capitalization:- Market Cap: $2.70092 billion
- Outstanding Shares: 48,204,000
Average Prices:- 50 Day Moving Avg: $53.05
- 200 Day Moving Avg: $50.07
- 52 Week Range: $35.84 - $67.74
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -9.41
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $49.12 million
- Price / Sales: 55.34
- Book Value: $7.25 per share
- Price / Book: 7.78
Profitability:- EBIDTA: ($238,380,000.00)
- Net Margins: -491.54%
- Return on Equity: -71.20%
- Return on Assets: -40.14%
Debt:- Current Ratio: 6.15%
- Quick Ratio: 6.15%
Misc:- Average Volume: 610,546 shs.
- Beta: 1.93
- Short Ratio: 12.68
Frequently Asked Questions for Agios Pharmaceuticals (NASDAQ:AGIO)
What is Agios Pharmaceuticals' stock symbol?
Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."
How were Agios Pharmaceuticals' earnings last quarter?
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) posted its quarterly earnings results on Thursday, May, 4th. The company reported ($1.56) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.80) by $0.24. The business earned $10.51 million during the quarter, compared to analyst estimates of $9.65 million. Agios Pharmaceuticals had a negative return on equity of 71.20% and a negative net margin of 491.54%. The business's revenue was down 66.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.64) earnings per share. View Agios Pharmaceuticals' Earnings History.
When will Agios Pharmaceuticals make its next earnings announcement?
Where is Agios Pharmaceuticals' stock going? Where will Agios Pharmaceuticals' stock price be in 2017?
11 analysts have issued twelve-month target prices for Agios Pharmaceuticals' shares. Their forecasts range from $45.00 to $90.00. On average, they expect Agios Pharmaceuticals' stock price to reach $62.88 in the next year. View Analyst Ratings for Agios Pharmaceuticals.
What are analysts saying about Agios Pharmaceuticals stock?
Here are some recent quotes from research analysts about Agios Pharmaceuticals stock:
- 1. Cann analysts commented, "This dinner and discussion with management, experts, and investors offered an update on AG-120 and an in-depth look at AG-221. Takeaways for AG-221 focused on outcomes and commercial use. AG-221 was found to have remarkable outcomes, especially in light of the difficult-to-treat population in the study. The enthusiasm expressed by Drs." (6/11/2017)
- 2. According to Zacks Investment Research, "Agios's shares have outperformed the Medical-Products industry so far this year. As a development-stage company, Agios depends heavily on Celgene for revenues. However, the collaboration with Celgene is encouraging as it provides Agios funds in the form of upfront, regulatory and commercial milestone payments plus royalties. In terms of the company’s pipeline, most of the candidates are in mid and early stages of development and thus, several years away from entering the market. Moreover, the decision to discontinue the development of AG-519 is disappointing. Stiff competition is another matter of concern for the company. Estimates have been going down lately ahead of the company’s Q1 earnings release. The company has mixed record of earnings surprises in recent quarters." (4/28/2017)
- 3. Cowen and Company analysts commented, "Agios ended 2016 with $574MM in cash, enough to last through 2018." (2/16/2017)
Who are some of Agios Pharmaceuticals' key competitors?
Some companies that are related to Agios Pharmaceuticals include bluebird bio (BLUE), Neurocrine Biosciences (NBIX), Clovis Oncology (CLVS), Intercept Pharmaceuticals (ICPT), BeiGene (BGNE), Juno Therapeutics (JUNO), Ultragenyx Pharmaceutical (RARE), China Biologic Products (CBPO), GW Pharmaceuticals PLC (GWPH), Axovant Sciences (AXON), Prothena Corporation PLC (PRTA), AveXis (AVXS), Aerie Pharmaceuticals (AERI), Spark Therapeutics (ONCE), Loxo Oncology (LOXO), Sarepta Therapeutics (SRPT), Radius Health (RDUS) and Halozyme Therapeutics (HALO).
Who are Agios Pharmaceuticals' key executives?
Agios Pharmaceuticals' management team includes the folowing people:
- David P. Schenkein M.D., President, Chief Executive Officer, Director
- Andrew Hirsch, Chief Financial Officer
- Scott Biller Ph.D., Chief Scientific Officer
- Christopher Bowden M.D., Chief Medical Officer
- Steven L. Hoerter, Chief Commercial Officer
- Lewis Clayton Cantley Ph.D., Director
- David Scadden M.D., Director
- Paul J. Clancy, Independent Director
- Ian T. Clark, Independent Director
- Kaye I. Foster-Cheek, Independent Director
Who owns Agios Pharmaceuticals stock?
Agios Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include
CELGENE EUROPEAN INVESTMENT COMPANY LLC
(12.40%), Handelsbanken Fonder AB (0.21%), Handelsinvest Investeringsforvaltning (0.06%), Creative Planning (0.03%), Aperio Group LLC (0.01%) and Daiwa SB Investments Ltd. (0.01%). Company insiders that own Agios Pharmaceuticals stock include Celgene European Investment Co, David P Schenkein, Glenn Goddard, John Duncan Higgons, Lewis Clayton Jr Cantley, Robert Nelsen and Scott Biller. View Institutional Ownership Trends for Agios Pharmaceuticals.
Who sold Agios Pharmaceuticals stock? Who is selling Agios Pharmaceuticals stock?
Agios Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Daiwa SB Investments Ltd.. Company insiders that have sold Agios Pharmaceuticals stock in the last year include David P Schenkein, Lewis Clayton Jr Cantley, Robert Nelsen and Scott Biller. View Insider Buying and Selling for Agios Pharmaceuticals.
Who bought Agios Pharmaceuticals stock? Who is buying Agios Pharmaceuticals stock?
How do I buy Agios Pharmaceuticals stock?
Shares of Agios Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Agios Pharmaceuticals' stock price today?
One share of Agios Pharmaceuticals stock can currently be purchased for approximately $56.39.
MarketBeat Community Rating for Agios Pharmaceuticals (NASDAQ AGIO)MarketBeat's community ratings are surveys of what our community members think about Agios Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Agios Pharmaceuticals (NASDAQ:AGIO) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 4 Hold Ratings, 7 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.64) |
| Consensus Price Target: | $62.88 (11.50% upside) |
Analysts' Ratings History for Agios Pharmaceuticals (NASDAQ:AGIO)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 6/26/2017 | Janney Montgomery Scott | Downgrade | Buy -> Neutral | | High |  |
| 6/11/2017 | Oppenheimer Holdings, Inc. | Set Price Target | Buy | $75.00 | Medium | |
| 6/11/2017 | Cann | Reiterated Rating | Buy | $75.00 | Medium | |
| 5/18/2017 | Canaccord Genuity | Set Price Target | Buy | $90.00 | Medium | |
| 4/18/2017 | Credit Suisse Group | Reiterated Rating | Outperform | $61.00 | High | |
| 2/16/2017 | Cowen and Company | Reiterated Rating | Buy | | N/A | |
| 1/17/2017 | CIBC | Upgrade | Market Perform -> Outperform | | N/A | |
| 12/19/2016 | Leerink Swann | Reiterated Rating | Market Perform | $56.00 -> $45.00 | N/A | |
| 12/16/2016 | Needham & Company LLC | Reiterated Rating | Buy | $60.00 -> $54.00 | N/A | |
| 8/19/2016 | BTIG Research | Initiated Coverage | Neutral | | N/A | |
| 8/10/2016 | Goldman Sachs Group, Inc. (The) | Reiterated Rating | Neutral | $46.00 | N/A | |
| 6/13/2016 | J P Morgan Chase & Co | Upgrade | Neutral -> Overweight | $50.00 -> $62.00 | N/A | |
| 5/18/2016 | SunTrust Banks, Inc. | Boost Price Target | Buy | $57.00 -> $65.00 | N/A | |
| 11/9/2015 | Roth Capital | Lower Price Target | Neutral | $114.00 -> $75.00 | N/A | |
| 7/22/2015 | Northland Securities | Initiated Coverage | Outperform | $132.00 | N/A | |
(Data available from 7/20/2015 forward)
Earnings History for Agios Pharmaceuticals (NASDAQ:AGIO)Earnings History by Quarter for Agios Pharmaceuticals (NASDAQ AGIO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/2/2017 | | ($1.56) | | | | | N/A | |
| 5/4/2017 | Q1 2017 | ($1.80) | ($1.56) | $9.65 million | $10.51 million | View | Listen | |
| 2/16/2017 | Q416 | ($1.51) | ($1.34) | $10.89 million | $22.65 million | View | Listen | |
| 11/3/2016 | Q316 | ($1.52) | ($1.63) | $7.82 million | $8.98 million | View | Listen | |
| 8/4/2016 | Q216 | ($0.48) | ($1.47) | $39.62 million | $6.98 million | View | Listen | |
| 5/5/2016 | Q116 | ($0.79) | ($0.61) | $20.94 million | $31.30 million | View | Listen | |
| 2/18/2016 | Q415 | ($0.27) | ($1.08) | $28.78 million | $6.22 million | View | Listen | |
| 11/5/2015 | Q315 | ($0.89) | ($1.07) | $17.21 million | $5.80 million | View | Listen | |
| 8/6/2015 | Q215 | ($0.46) | ($0.85) | $25.75 million | $13.20 million | View | Listen | |
| 5/7/2015 | Q115 | ($0.86) | ($0.13) | $10.86 million | $34.20 million | View | Listen | |
| 2/17/2015 | Q414 | ($0.55) | ($0.76) | $10.94 million | $14.64 million | View | Listen | |
| 11/7/2014 | Q314 | ($0.53) | $0.10 | $8.45 million | $33.90 million | View | Listen | |
| 8/7/2014 | Q2 | ($0.47) | ($0.54) | $11.00 million | $8.41 million | View | Listen | |
| 5/8/2014 | Q1 | ($0.37) | ($0.39) | $7.19 million | $8.41 million | View | Listen | |
| 3/6/2014 | Q4 | ($0.34) | ($0.40) | $6.19 million | $6.70 million | View | Listen | |
| 11/7/2013 | | ($0.28) | ($0.47) | | | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)2017 EPS Consensus Estimate: ($7.60)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | ($1.86) | ($1.78) | ($1.81) |
| Q2 2017 | 3 | ($1.92) | ($1.80) | ($1.88) |
| Q3 2017 | 2 | ($1.98) | ($1.96) | ($1.97) |
| Q4 2017 | 1 | ($1.95) | ($1.95) | ($1.95) |
(Data provided by Zacks Investment Research)
Dividend History for Agios Pharmaceuticals (NASDAQ:AGIO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Agios Pharmaceuticals (NASDAQ:AGIO)Insider Ownership Percentage: 10.55%
Institutional Ownership Percentage: 83.83%
Insider Trades by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/7/2017 | Scott Biller | Insider | Sell | 2,146 | $55.00 | $118,030.00 | |
| 7/3/2017 | David P Schenkein | CEO | Sell | 3,000 | $51.18 | $153,540.00 | |
| 6/21/2017 | Scott Biller | Insider | Sell | 4,292 | $55.00 | $236,060.00 | |
| 6/14/2017 | Lewis Clayton Jr. Cantley | Director | Sell | 2,000 | $50.87 | $101,740.00 | |
| 6/7/2017 | David P Schenkein | CEO | Sell | 3,000 | $50.02 | $150,060.00 | |
| 5/25/2017 | Lewis Clayton Jr. Cantley | Director | Sell | 2,036 | $47.10 | $95,895.60 | |
| 5/1/2017 | David P Schenkein | CEO | Sell | 3,000 | $50.06 | $150,180.00 | |
| 4/24/2017 | Celgene European Investment Co | Major Shareholder | Buy | 624,575 | $49.50 | $30,916,462.50 | |
| 4/18/2017 | Lewis Clayton Jr. Cantley | Director | Sell | 5,090 | $54.37 | $276,743.30 | |
| 4/17/2017 | Lewis Clayton Jr. Cantley | Director | Sell | 2,036 | $55.24 | $112,468.64 | |
| 4/3/2017 | David P Schenkein | CEO | Sell | 3,000 | $58.62 | $175,860.00 | |
| 4/3/2017 | Scott Biller | Insider | Sell | 2,146 | $58.03 | $124,532.38 | |
| 3/23/2017 | Lewis Clayton Jr. Cantley | Director | Sell | 2,036 | $53.11 | $108,131.96 | |
| 3/20/2017 | Scott Biller | Insider | Sell | 6,438 | $55.00 | $354,090.00 | |
| 3/6/2017 | Robert Nelsen | Director | Sell | 40,599 | $50.84 | $2,064,053.16 | |
| 2/28/2017 | Robert Nelsen | Director | Sell | 243,082 | $49.36 | $11,998,527.52 | |
| 2/23/2017 | Robert Nelsen | Director | Sell | 135,364 | $49.37 | $6,682,920.68 | |
| 2/16/2017 | David P Schenkein | CEO | Sell | 6,000 | $50.01 | $300,060.00 | |
| 10/27/2016 | Lewis Clayton Jr. Cantley | Director | Sell | 2,504 | $48.94 | $122,545.76 | |
| 10/5/2016 | Scott Biller | Insider | Sell | 5,000 | $55.00 | $275,000.00 | |
| 9/28/2016 | Lewis Clayton Jr. Cantley | Director | Sell | 627 | $54.00 | $33,858.00 | |
| 9/27/2016 | Lewis Clayton Jr. Cantley | Director | Sell | 627 | $54.15 | $33,952.05 | |
| 9/20/2016 | Scott Biller | Insider | Sell | 5,000 | $50.00 | $250,000.00 | |
| 8/30/2016 | Lewis Clayton Jr. Cantley | Director | Sell | 627 | $36.81 | $23,079.87 | |
| 8/29/2016 | Lewis Clayton Jr. Cantley | Director | Sell | 627 | $37.81 | $23,706.87 | |
| 7/26/2016 | Lewis Clayton Jr. Cantley | Director | Sell | 2,504 | $42.80 | $107,171.20 | |
| 7/25/2016 | Lewis Clayton Jr. Cantley | Director | Sell | 627 | $41.85 | $26,239.95 | |
| 6/28/2016 | Lewis Clayton Jr. Cantley | Director | Sell | 2,504 | $41.88 | $104,867.52 | |
| 6/27/2016 | Lewis Clayton Jr. Cantley | Director | Sell | 627 | $40.37 | $25,311.99 | |
| 6/8/2016 | Scott Biller | Insider | Sell | 27,500 | $65.00 | $1,787,500.00 | |
| 5/26/2016 | Lewis Clayton Jr. Cantley | Director | Sell | 2,504 | $51.69 | $129,431.76 | |
| 4/26/2016 | Lewis Clayton Jr. Cantley | Director | Sell | 2,504 | $53.44 | $133,813.76 | |
| 4/25/2016 | Lewis Clayton Jr. Cantley | Director | Sell | 627 | $55.00 | $34,485.00 | |
| 3/30/2016 | Lewis Clayton Jr. Cantley | Director | Sell | 2,504 | $37.19 | $93,123.76 | |
| 2/26/2016 | Lewis Clayton Jr. Cantley | Director | Sell | 2,504 | $37.90 | $94,901.60 | |
| 1/29/2016 | Lewis Clayton Jr. Cantley | Director | Sell | 2,504 | $42.93 | $107,496.72 | |
| 12/29/2015 | Lewis Clayton Jr. Cantley | Director | Sell | 10,664 | $64.93 | $692,413.52 | |
| 12/15/2015 | John Duncan Higgons | COO | Sell | 20,000 | $50.09 | $1,001,800.00 | |
| 11/17/2015 | Lewis Clayton Jr. Cantley | Director | Sell | 9,408 | $59.83 | $562,880.64 | |
| 11/16/2015 | John Duncan Higgons | COO | Sell | 20,000 | $61.51 | $1,230,200.00 | |
| 11/2/2015 | Scott Biller | insider | Sell | 5,500 | $77.12 | $424,160.00 | |
| 10/23/2015 | Lewis Clayton Jr. Cantley | Director | Sell | 9,704 | $61.16 | $593,496.64 | |
| 10/15/2015 | John Duncan Higgons | COO | Sell | 20,000 | $71.04 | $1,420,800.00 | |
| 9/30/2015 | Scott Biller | insider | Sell | 5,500 | $70.44 | $387,420.00 | |
| 9/25/2015 | Lewis Clayton Jr. Cantley | Director | Sell | 9,704 | $83.25 | $807,858.00 | |
| 9/24/2015 | Glenn Goddard | SVP | Sell | 6,000 | $85.97 | $515,820.00 | |
| 9/15/2015 | John Duncan Higgons | COO | Sell | 20,000 | $91.11 | $1,822,200.00 | |
| 8/18/2015 | Lewis Clayton Jr. Cantley | Director | Sell | 9,704 | $94.94 | $921,297.76 | |
| 8/17/2015 | John Duncan Higgons | COO | Sell | 20,000 | $92.24 | $1,844,800.00 | |
| 7/23/2015 | Glenn Goddard | SVP | Sell | 7,000 | $120.45 | $843,150.00 | |
| 7/20/2015 | Scott Biller | Insider | Sell | 5,500 | $113.87 | $626,285.00 | |
| 7/17/2015 | Glenn Goddard | SVP | Sell | 13,000 | $113.71 | $1,478,230.00 | |
| 7/16/2015 | John Duncan Higgons | COO | Sell | 20,000 | $114.02 | $2,280,400.00 | |
| 7/16/2015 | Lewis Clayton Jr. Cantley | Director | Sell | 9,704 | $114.28 | $1,108,973.12 | |
| 6/25/2015 | Lewis Clayton Jr. Cantley | Director | Sell | 9,704 | $105.13 | $1,020,181.52 | |
| 6/15/2015 | John Duncan Higgons | COO | Sell | 7,000 | $105.23 | $736,610.00 | |
| 6/8/2015 | Scott Biller | Insider | Sell | 5,500 | $121.85 | $670,175.00 | |
| 6/1/2015 | Christopher Bowden | Insider | Sell | 5,000 | $120.67 | $603,350.00 | |
| 6/1/2015 | David P Schenkein | CEO | Sell | 13,000 | $120.67 | $1,568,710.00 | |
| 5/27/2015 | David P Schenkein | CEO | Sell | 8,929 | $120.05 | $1,071,926.45 | |
| 5/27/2015 | Glenn Goddard | SVP | Sell | 2,171 | $120.05 | $260,628.55 | |
| 5/20/2015 | Lewis Clayton Jr. Cantley | Director | Sell | 9,704 | $116.64 | $1,131,874.56 | |
| 5/15/2015 | John Duncan Higgons | COO | Sell | 7,417 | $112.89 | $837,305.13 | |
| 5/12/2015 | David P Schenkein | CEO | Sell | 5,200 | $110.02 | $572,104.00 | |
| 5/8/2015 | David P Schenkein | CEO | Sell | 3,900 | $101.32 | $395,148.00 | |
| 5/7/2015 | Scott Biller | Insider | Sell | 5,500 | $96.32 | $529,760.00 | |
| 4/24/2015 | Lewis Clayton Jr. Cantley | Director | Sell | 9,704 | $105.15 | $1,020,375.60 | |
| 4/15/2015 | John Duncan Higgons | COO | Sell | 6,583 | $99.54 | $655,271.82 | |
| 4/13/2015 | David P Schenkein | CEO | Sell | 3,900 | $100.03 | $390,117.00 | |
| 4/8/2015 | Scott Biller | Insider | Sell | 5,500 | $97.64 | $537,020.00 | |
| 4/1/2015 | David P Schenkein | CEO | Sell | 3,900 | $92.54 | $360,906.00 | |
| 3/27/2015 | Lewis Clayton Jr. Cantley | Director | Sell | 9,704 | $93.58 | $908,100.32 | |
| 3/16/2015 | Glenn Goddard | SVP | Sell | 10,000 | $106.24 | $1,062,400.00 | |
| 3/16/2015 | John Duncan Higgons | COO | Sell | 7,000 | $106.24 | $743,680.00 | |
| 3/16/2015 | Scott Biller | Insider | Sell | 5,500 | $106.81 | $587,455.00 | |
| 3/2/2015 | David P Schenkein | CEO | Sell | 7,800 | $107.05 | $834,990.00 | |
| 2/13/2015 | David P Schenkein | CEO | Sell | 1,471 | $120.22 | $176,843.62 | |
| 2/13/2015 | Glenn Goddard | SVP | Sell | 1,316 | $120.31 | $158,327.96 | |
| 2/11/2015 | Glenn Goddard | SVP | Sell | 16,513 | $107.12 | $1,768,872.56 | |
| 2/9/2015 | Glenn Goddard | SVP | Sell | 15,000 | $105.81 | $1,587,150.00 | |
| 2/2/2015 | David P Schenkein | CEO | Sell | 10,400 | $114.31 | $1,188,824.00 | |
| 1/2/2015 | David P Schenkein | CEO | Sell | 13,000 | $110.08 | $1,431,040.00 | |
| 1/2/2015 | John Duncan Higgons | COO | Sell | 12,000 | $110.08 | $1,320,960.00 | |
| 1/2/2015 | Scott Biller | Insider | Sell | 4,500 | $110.08 | $495,360.00 | |
| 12/16/2014 | Celgene European Investment Co | Major Shareholder | Buy | 228,645 | $110.75 | $25,322,433.75 | |
| 12/16/2014 | John Maraganore | Director | Buy | 1,806 | $110.75 | $200,014.50 | |
| 12/1/2014 | David P Schenkein | CEO | Sell | 13,000 | $97.03 | $1,261,390.00 | |
| 12/1/2014 | John Duncan Higgons | COO | Sell | 12,000 | $97.03 | $1,164,360.00 | |
| 12/1/2014 | Scott Biller | Insider | Sell | 4,500 | $97.03 | $436,635.00 | |
| 11/3/2014 | Glenn Goddard | SVP | Sell | 2,000 | $81.71 | $163,420.00 | |
| 11/3/2014 | John Duncan Higgons | COO | Sell | 13,000 | $81.71 | $1,062,230.00 | |
| 11/3/2014 | Scott Biller | Insider | Sell | 4,500 | $81.71 | $367,695.00 | |
| 10/1/2014 | Glenn Goddard | SVP | Sell | 1,500 | $60.07 | $90,105.00 | |
| 10/1/2014 | John Duncan Higgons | COO | Sell | 13,000 | $60.07 | $780,910.00 | |
| 10/1/2014 | Scott Biller | Insider | Sell | 4,500 | $60.07 | $270,315.00 | |
| 9/26/2014 | David P Schenkein | CEO | Sell | 60,000 | $62.68 | $3,760,800.00 | |
| 9/26/2014 | Glenn Goddard | SVP | Sell | 17,500 | $56.53 | $989,275.00 | |
| 9/19/2014 | Scott Biller | Insider | Sell | 37,996 | $50.45 | $1,916,898.20 | |
| 9/2/2014 | Glenn Goddard | SVP | Sell | 10,000 | $46.30 | $463,000.00 | |
| 9/2/2014 | John Duncan Higgons | COO | Sell | 13,000 | $46.30 | $601,900.00 | |
| 9/2/2014 | Scott Biller | Insider | Sell | 4,500 | $46.30 | $208,350.00 | |
| 8/26/2014 | John Duncan Higgons | COO | Sell | 5,000 | $45.05 | $225,250.00 | |
| 8/11/2014 | David P Schenkein | CEO | Sell | 4,530 | $40.17 | $181,970.10 | |
| 7/1/2014 | David P Schenkein | CEO | Sell | 13,000 | $46.52 | $604,760.00 | |
| 7/1/2014 | Glenn Goddard | SVP | Sell | 3,500 | $46.52 | $162,820.00 | |
| 7/1/2014 | John Duncan Higgons | COO | Sell | 12,000 | $46.52 | $558,240.00 | |
| 7/1/2014 | Scott Biller | Insider | Sell | 4,500 | $46.52 | $209,340.00 | |
| 6/23/2014 | John Maraganore | Director | Buy | 2,300 | $43.98 | $101,154.00 | |
| 6/20/2014 | Scott Biller | Insider | Sell | 2,004 | $50.05 | $100,300.20 | |
| 6/13/2014 | John Duncan Higgons | COO | Sell | 5,000 | $45.27 | $226,350.00 | |
| 6/3/2014 | John Duncan Higgons | COO | Sell | 7,000 | $34.47 | $241,290.00 | |
| 5/6/2014 | John Duncan Higgons | COO | Sell | 5,000 | $45.73 | $228,650.00 | |
| 5/1/2014 | Glenn Goddard | SVP | Sell | 2,000 | $42.39 | $84,780.00 | |
| 5/1/2014 | John Duncan Higgons | COO | Sell | 7,000 | $42.39 | $296,730.00 | |
| 5/1/2014 | Scott Biller | Insider | Sell | 4,500 | $42.39 | $190,755.00 | |
| 4/29/2014 | Celgene European Investment Co | major shareholder | Buy | 294,800 | $44.00 | $12,971,200.00 | |
| 4/29/2014 | John Maraganore | Director | Buy | 2,250 | $44.00 | $99,000.00 | |
| 4/7/2014 | Glenn Goddard | SVP | Sell | 2,000 | $45.17 | $90,340.00 | |
| 4/7/2014 | John Duncan Higgons | COO | Sell | 3,000 | $45.17 | $135,510.00 | |
| 4/1/2014 | Glenn Goddard | SVP | Sell | 4,000 | $38.08 | $152,320.00 | |
| 4/1/2014 | John Duncan Higgons | COO | Sell | 12,000 | $38.08 | $456,960.00 | |
| 4/1/2014 | Scott Biller | Insider | Sell | 4,500 | $38.08 | $171,360.00 | |
| 3/7/2014 | Glenn Goddard | SVP | Sell | 17,468 | $42.11 | $735,577.48 | |
| 3/7/2014 | John Duncan Higgons | COO | Sell | 14,646 | $41.41 | $606,490.86 | |
| 3/3/2014 | John Duncan Higgons | COO | Sell | 8,000 | $29.85 | $238,800.00 | |
| 3/3/2014 | Scott Biller | Insider | Sell | 6,000 | $29.85 | $179,100.00 | |
| 2/10/2014 | Glenn Goddard | SVP | Sell | 6,000 | $30.44 | $182,640.00 | |
| 1/27/2014 | Glenn Goddard | SVP | Sell | 7,000 | $26.29 | $184,030.00 | |
| 1/21/2014 | Glenn Goddard | SVP | Sell | 10,000 | $34.71 | $347,100.00 | |
| 7/29/2013 | Celgene European Investment Co | Major Shareholder | Buy | 708,333 | $18.00 | $12,749,994.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Agios Pharmaceuticals (NASDAQ:AGIO)
Latest Headlines for Agios Pharmaceuticals (NASDAQ:AGIO)
| Source: |
|
| Date | Headline |
|---|
 | Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Upgraded to "Buy" by BidaskClub
www.americanbankingnews.com - July 16 at 4:00 PM |
| Zacks: Brokerages Expect Agios Pharmaceuticals, Inc. (AGIO) Will Post Quarterly Sales of $11.52 Million
www.americanbankingnews.com - July 16 at 8:16 AM |
| Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Expected to Announce Earnings of -$1.52 Per Share
www.americanbankingnews.com - July 14 at 4:48 PM |
 | Newman Ferrara LLP Announces Corporate Governance Investigation of Agios Pharmaceuticals Inc. - AGIO - Business Wire (press release)
www.businesswire.com - July 12 at 4:03 PM |
 | Newman Ferrara LLP Announces Corporate Governance Investigation of Agios Pharmaceuticals Inc. - AGIO
finance.yahoo.com - July 12 at 4:03 PM |
| Insider Selling: Agios Pharmaceuticals, Inc. (AGIO) Insider Sells 2,146 Shares of Stock
www.americanbankingnews.com - July 11 at 8:20 PM |
| David P. Schenkein Sells 3,000 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock
www.americanbankingnews.com - July 6 at 8:04 PM |
 | Agios/Celgene's Leukemia Candidate Positive in Phase I/II
www.zacks.com - June 27 at 8:30 PM |
 | Agios/Celgene's Leukemia Candidate Positive in Phase I/II - Nasdaq
www.nasdaq.com - June 27 at 3:29 PM |
| Agios/Celgene's Leukemia Candidate Positive in Phase I/II
finance.yahoo.com - June 27 at 3:29 PM |
| Agios Pharmaceuticals, Inc. (AGIO) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - June 27 at 12:34 PM |
 | Mid-Morning Market Update: Markets Open Higher; Durable-Goods Orders Fall 1.1% - Benzinga
www.benzinga.com - June 26 at 8:55 PM |
| 12 Biggest Mid-Day Losers For Monday | Benzinga - Benzinga
www.benzinga.com - June 26 at 8:55 PM |
| Mid-Morning Market Update: Markets Open Higher; Durable-Goods Orders Fall 1.1%
www.nasdaq.com - June 26 at 3:53 PM |
| Agio Pharma Sinks on Midstage Trial
finance.yahoo.com - June 26 at 3:53 PM |
| Biotech Rally Stumbles As These Small Caps Pull Back
finance.yahoo.com - June 26 at 3:53 PM |
| Agios Pharmaceuticals, Inc. (AGIO) Cut to Neutral at Janney Montgomery Scott
www.americanbankingnews.com - June 26 at 12:16 PM |
 | Agios Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating ...
www.globenewswire.com - June 25 at 8:35 PM |
| Agios Pharmaceuticals, Inc. (AGIO) Upgraded to Hold by ValuEngine
www.americanbankingnews.com - June 25 at 12:10 AM |
| Agios Pharma Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating AG-348's Potential as ... - Benzinga
www.benzinga.com - June 24 at 8:26 PM |
| Agios Pharma Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating AG-348's Potential as First Disease-modifying Treatment for Patients with PKR #EHA2017
finance.yahoo.com - June 24 at 8:26 PM |
| Agios Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating AG-348's Potential as the First ... - GlobeNewswire (press release)
globenewswire.com - June 24 at 3:25 PM |
| Agios Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating AG-348’s Potential as the First Disease-modifying Treatment for Patients with Pyruvate Kinase Deficiency
finance.yahoo.com - June 24 at 3:24 PM |
| New Data from Phase 1/2 Trial of Oral IDHIFA® (enasidenib) Demonstrate Durable Complete Responses in Patients with IDH2 Mutant Relapsed or Refractory AML
finance.yahoo.com - June 24 at 3:24 PM |
| Scott Biller Sells 4,292 Shares of Agios Pharmaceuticals, Inc. (AGIO) Stock
www.americanbankingnews.com - June 23 at 7:32 PM |
 | Celgene: I Don't Necessarily Understand The Science, But I Love The Numbers - Seeking Alpha
seekingalpha.com - June 22 at 3:23 PM |
| Agios Pharmaceuticals, Inc. (AGIO) Expected to Post Quarterly Sales of $11.52 Million
www.americanbankingnews.com - June 22 at 10:35 AM |
 | Myelodysplastic Syndrome Pipeline Therapeutic Drugs and ... - MarketWatch
www.marketwatch.com - June 21 at 2:09 AM |
| -$1.52 EPS Expected for Agios Pharmaceuticals, Inc. (AGIO) This Quarter
www.americanbankingnews.com - June 20 at 2:24 PM |
| Agios Pharmaceuticals, Inc. (AGIO) Director Sells $101,740.00 in Stock
www.americanbankingnews.com - June 15 at 7:42 PM |
| ETFs with exposure to Agios Pharmaceuticals, Inc. : June 15, 2017
finance.yahoo.com - June 15 at 4:59 PM |
| Agios Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AGIO) : June 14, 2017
finance.yahoo.com - June 14 at 3:25 PM |
| Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AGIO-US : June 13, 2017
finance.yahoo.com - June 13 at 11:38 AM |
| Agios Pharmaceuticals, Inc. (AGIO) PT Set at $75.00 by Oppenheimer Holdings, Inc.
www.americanbankingnews.com - June 11 at 11:32 PM |
| Agios Pharmaceuticals' (AGIO) "Buy" Rating Reaffirmed at Cann
www.americanbankingnews.com - June 11 at 9:34 PM |
| Insider Selling: Agios Pharmaceuticals Inc (AGIO) CEO Sells 3,000 Shares of Stock
www.americanbankingnews.com - June 8 at 7:52 PM |
| Agios (AGIO) Up 2.6% Since Earnings Report: Can It Continue? - Nasdaq
www.nasdaq.com - June 8 at 8:01 AM |
| Agios (AGIO) Up 2.6% Since Earnings Report: Can It Continue?
finance.yahoo.com - June 8 at 8:00 AM |
| Celgene and Agios Announce Data on Idhifa for Leukemia
finance.yahoo.com - June 7 at 3:30 PM |
| Updated Data from Phase 1 Trial of Oral IDHIFA® (enasidenib) Demonstrate Complete Responses and Duration of Response in Patients with Relapsed or Refractory AML and an IDH2 ...
www.businesswire.com - June 7 at 5:13 AM |
 | Celgene (CELG) & Agios Pharmaceuticals (AGIO) Presents Updated Data from Phase 1 Trial of Oral IDHIFA (Enasidenib)
www.streetinsider.com - June 7 at 5:13 AM |
 | BRIEF-Agios Pharmaceuticals says IDHIFA NDA given PDUFA action date of Aug. 30
www.reuters.com - June 7 at 5:13 AM |
| BRIEF-Agios Pharmaceuticals says IDHIFA NDA given PDUFA action date of Aug. 30 - Reuters
www.reuters.com - June 6 at 3:37 PM |
| Celgene (CELG) & Agios Pharmaceuticals (AGIO) Presents Updated ... - StreetInsider.com
www.streetinsider.com - June 6 at 3:37 PM |
| Updated Data from Phase 1 Trial of Oral IDHIFA® (enasidenib) Demonstrate Complete Responses and Duration of Response in Patients with Relapsed or Refractory AML and an IDH2 Mutation
finance.yahoo.com - June 6 at 3:37 PM |
| Agios Pharma (AGIO) Delivers Phase 1 Data from Dose-Escalation and Expansion Cohorts of AG-120 (Ivosidenib) at ASCO Meetings
www.streetinsider.com - June 5 at 1:36 PM |
| Agios Presents Phase 1 Data from Dose-Escalation and Expansion Cohorts of AG ...
globenewswire.com - June 4 at 8:24 PM |
| Agios Presents Phase 1 Data from Dose-Escalation and Expansion Cohorts of AG-120 (Ivosidenib) in Patients with ... - GlobeNewswire (press release)
www.globenewswire.com - June 3 at 3:25 PM |
| Agios Presents Phase 1 Data from Dose-Escalation and Expansion Cohorts of AG-120 (Ivosidenib) in Patients with Previously Treated IDH1 Mutant Positive Cholangiocarcinoma
finance.yahoo.com - June 3 at 3:25 PM |
| Agios Pharmaceuticals Inc (AGIO) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 2 at 9:00 AM |
Agios Pharmaceuticals (AGIO) Chart for Thursday, July, 20, 2017
